Aurinia Pharmaceuticals (AUPH) Operating Income Growth (1y) (2020 - 2026)
Aurinia Pharmaceuticals (AUPH) Operating Income Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | -24.89% |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.39 Bn | 467.60 Bn | 1.35 Bn | 2,150.96% |
| 5 | Vertex Pharmaceuticals | 122.08 Bn | 114.83 Bn | 2.59 Bn | 80.62% |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn | 8.65% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.97 Bn | 50.78 Bn | 1.41 Bn | 145.20% |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.46 Bn | 959.66 Mn | 1,386.07% |
| 10 | Aurinia Pharmaceuticals | 2.05 Bn | 1.68 Bn | 71.20 Mn | 89.60% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 89.60% |
| Dec 31, 2025 | 2,091.55% |
| Sep 30, 2025 | 153.19% |
| Jun 30, 2025 | 1,427.36% |
| Mar 31, 2025 | 264.85% |
| Dec 31, 2024 | 94.38% |
| Sep 30, 2024 | 172.24% |
| Jun 30, 2024 | 90.64% |
| Mar 31, 2024 | 55.20% |
| Dec 31, 2023 | -5.60% |
| Sep 30, 2023 | -71.21% |
| Jun 30, 2023 | 55.07% |
| Mar 31, 2023 | 21.90% |
| Dec 31, 2022 | 14.08% |
| Sep 30, 2022 | 81.14% |
| Jun 30, 2022 | 23.65% |
| Mar 31, 2022 | 25.05% |
| Dec 31, 2021 | -306.17% |
| Sep 30, 2021 | -19.00% |
| Jun 30, 2021 | -75.46% |